[CCNU in the chemotherapy of tumours of the central nervous system (author's transl)].
This study concerns 59 patients with primary and metastatic tumors of the CNS. After surgery, each patients followed a therapeutic protocol requiring Radiotherapy (5500 Rads for 6 weeks) and antiblastic monochemotherapy with CCNU (130 MG/M2/D p.o. every 8 weeks). The results were evaluated according to Wilson's (1975) criteria of response to therapy. CCNU significantly improved the survival time in comparison to the data given for conventional treatment.
D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D004341:Drug Evaluation; D005260:Female; D005910:Glioma / Q000188:drug therapy; D006801:Humans; D008130:Lomustine / Q000627:therapeutic use*; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D011879:Radiotherapy Dosage
D009607:Nitrosourea Compounds; D008130:Lomustine
L'uso del CCNU nella chemioterapia dei tumori del sistema nervoso centrale.